The instant disclosure provides antibodies that specifically bind to LAG-3 (e.g., human LAG-3) and antagonize LAG-3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

The present disclosure provides Siglec ligands that have particular linkers. Also provided are conjugates that include a biologically active substance that is covalently bonded to the connecting group of the Siglec ligands. For instance, the biologically active substance can be a biotherapeutic or an autoantigen. The linkers can have advantageous properties that improve the technical qualities of the corresponding conjugates.

The present disclosure relates to activatable IL-18 immunocytokine compositions comprising antibodies or antigen binding fragments specific for immune cell antigens and activatable IL-18 polypeptides. Also provided herein are methods of treatment with and methods of manufacture of activatable immunocytokine compositions. Activatable IL-18 polypeptides usable in immunocytokines are also encompassed by the present disclosure.

The instant disclosure provides antibodies that specifically bind to LAG-3 (e.g., human LAG-3) and antagonize LAG-3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

The present invention relates to a process for preparing antibody-drug conjugates wherein therapeutic moieties are conjugated to one or more engineered cysteines as well as to one or more reduced interchain cysteines via a cleavable or non-cleavable linker.

Provided herein is a vaccination composition that comprises a recombinant immune complex (RIC) that includes an immunoglobulin heavy chain; an epitope tag, wherein the immunoglobulin heavy chain binds the epitope tag; and at least a fragment of a herpes simplex virus (HSV) type 2 glycoprotein D (HSV2 glycoprotein D). Related methods, recombinant vectors, and other aspects are also provided.

Provided herein are isolated anti-CEACAM5 antibodies, antigen binding portions thereof, bispecific antibodies, and conjugates (e.g., antibody-drug conjugates), which specifically bind to CEACAM5 and are internalized by CEACAM5 expressing cells. Also provided are nucleic acids encoding the anti-CEACAM5 antibodies and antigen binding portions, methods for treating cancer comprising administration of CEACAM5-targeted antibodies, antigen binding portions thereof, bispecific antibodies, and conjugates and/or associated therapies, as well as methods of diagnosis, and kits.

The present application relates to an antigen binding protein comprising at least one CDR of a heavy chain variable region and at least one CDR of a light chain variable region, wherein said heavy chain variable region comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 73 or 74, and the light chain variable region comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 75 or 76.